Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ipilimumab Clear all
Completed Phase 1 Interventional

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

NCT05444530
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
VAC85135, Ipilimumab
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 24, 2026, 1:52 AM EDT
Not listed Phase 2 Interventional

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

NCT01565837
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
Drug · Radiation
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Novel Adjuvants for Peptide-Based Melanoma Vaccines

NCT00028431
View directory record Official record
Conditions
Melanoma
Interventions
MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 24, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

NCT05144529
View directory record Official record
Conditions
Lung Cancer Metastatic
Interventions
Nivolumab, Ipilimumab, Evolocumab
Drug
Lead sponsor
Eziafa Oduah, MD, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938
View directory record Official record
Conditions
Advanced or Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
11
States / cities
Tampa, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 24, 2026, 1:52 AM EDT
Active, not recruiting No phase listed Observational

Biomarkers of Immune-Related Toxicity

NCT03409016
View directory record Official record
Conditions
Cancer, Metastatic Cancer
Interventions
Blood Testing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 24, 2026, 1:52 AM EDT
Terminated Phase 1 Interventional

GVAX Plus Checkpoint Blockade in Neuroblastoma

NCT04239040
View directory record Official record
Conditions
Neuroblastoma, Pediatric Solid Tumor
Interventions
Tissue collection, GVAX vaccine, Nivolumab, Ipilimumab
Procedure · Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Early Phase 1 Interventional

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

NCT00972933
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

NCT01323517
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Melphalan and Dactinomycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 24, 2026, 1:52 AM EDT
Terminated Phase 1 Interventional

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03565406
View directory record Official record
Conditions
Melanoma
Interventions
Mocetinostat Induction Phase + Ipilimumab + Nivolumab, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

NCT00077532
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 24, 2026, 1:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609
View directory record Official record
Conditions
Lung Cancer - Non Small Cell Squamous
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

NCT02231749
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Sunitinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
37
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

NCT02829931
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 24, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

NCT07532902
View directory record Official record
Conditions
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
Interventions
BMS-986504, Ipilimumab, Nivolumab, 5-FU, Leucovorin, Oxaliplatin, Gemcitabine, Platinum
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

NCT03029780
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Opdivo, Yervoy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Jacksonville, Florida • Iowa City, Iowa • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jul 24, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

NCT07128680
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Dietary Supplement · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766
View directory record Official record
Conditions
Kidney Cancer
Interventions
NeoVax, Ipilimumab
Drug
Lead sponsor
Patrick Ott, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129
View directory record Official record
Conditions
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

NCT05116202
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tiragolumab, RO7247669 600 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

NCT02073123
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

NCT01832870
View directory record Official record
Conditions
Prostate Cancer, Castrate Resistant Prostate Cancer
Interventions
sipuleucel-T, ipilimumab
Drug
Lead sponsor
Prostate Oncology Specialists, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Marina del Rey, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Jul 24, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

NCT03552380
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Nivolumab, Ipilimumab
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jul 24, 2026, 1:52 AM EDT